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ABSTRACT  
Developing countries are more vulnerable to the Vector borne diseases, than 
developed countries. Incidence of Malaria is steadily increasing and number 
of deaths as well; is a serious problem in Africa; every five (20%) childhood 
deaths are due to the effects of the disease and every 30 seconds a child dies 
from malaria. The problem of Malaria acquired new dimensions such as 
resistance of vectors to chemical insecticides and drug resistance in strains 
of Plasmodium Vivax and Plasmodium Falciparum. These are the serious 
obstacles in the control of Malaria and hence there is a serious need to 
develop alternate strategies to control Malaria.  
Central Council for Research in Ayurvedic Sciences is carrying out clinical 
trial on different Vector Borne Diseases like Malaria, Filariasis etc since 
seventies. Trial carried out with herbal and herbo-mineral drugs like AYUSH-
64, Saptaparnatwak ghanavati, Guduci satva, Spatika Bhasma, Kiratatiktadi 
compound, Parijatapatra ghanavati etc. on Plasmodium Vivax Malaria. The 
present paper deals with the details of those drugs and concludes the best 
drug for control of Malaria.  
 
INTRODUCTION 
 Malaria is one of the most prevalent and 
deadly infectious diseases in Asia, Africa and the 
America. All over the world, every year around 250 
million cases are registered and nearly one million 
deaths are taking place. United Nations incorporated it 
as one of the Millennium Development Goals (6C) with 
the aim of combating Malaria. As per the World 
Malaria Report 2015(1), India accounts for 70% of the 
total malaria incidence in the South-East Asia Region 
and more than 80% of the global Plasmodium vivax 
burden is contributed by three countries including 
India. India alone contributes nearly half (46%) of the 
global population at risk and two thirds of those are at 
stable risk(2). It is endemic across around 44 million 
km, approximately 1/3rd of earth land(3).  
Malaria is caused by protozoa of the genus 
Plasmodium; species of falciparum, vivax, ovale, 
malariae. Plasmodium vivax malaria is found across a 
large area of the globe and potentially affects larger 
number of people than Plasmodium falciparum 
malaria.  
Malaria description in Ayurveda 
 In Ayurvedic literature Malaria fever is known 
as Vishamajwara (intermittent fever). Since Vedic time 
references for fever is available and is known as 
Takma in Atharvaveda. Carakasamhita, the first 
detailed compendium of Ayurveda starts its 
therapeutics part with the treatment of Jvara (fever), 
shows the importance of treatment of fever in 
Ayurveda. There are numerous kinds of fevers 
described in Ayurveda, like Santatajvara, 
Sannipatajvara, Vishamajvara, Abhishangajvara, 
Abhighatajajvara etc(4).  
 Fever that manifests with irregular onset 
(Vishama arambha) and remission (Visarga) is called 
as Vishamajvara (intermittent fever). It is described in 
Kashyapasamhita that when all the three or two 
humours vitiate and reach Rasavaha dhamani 
(channels carrying rasa kind of tissue elements) 
produce Vishamajvara. This can be compared with 
malarial fever based on its irregular onset and 
remission. Clinical features of Vishamajvara (Malaria) 
are fever with irregular onset and remission, excessive 
thirst, heaviness in the body, generalized body pains, 
headache, rigors, nausea, vomiting etc.  
Necessity of new, safe and effective drug 
 Incidence of Malaria is steadily increasing and 
number of deaths as well; the problem of Malaria 
acquired new dimensions such as resistance of vectors 
to chemical insecticides and drug resistance in strains 
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of Plasmodium Vivax and Plasmodium Falciparum. 
These are the serious obstacles in the control of 
Malaria and hence there is a serious need to develop 
alternate strategies to control Malaria. Very worrying 
reports from South East Asia is potential resistance to 
artemisinins which form the basis of first line anti-
malarial treatment in many countries. 
 World Health Organization has advised to 
have a stock of other equivalent drugs for use when 
resistance occurs, as far as chloroquine is concerned. 
By this it appears that margin of security of malaria 
chemotherapy is very narrow and there is great need 
to develop new and better drugs. More over Malaria 
parasite develops resistance easily to allopathic ante-
malarial drugs due to their simple chemical structure. 
As far as herbal and herbo-mineral drugs are 
concerns, it is highly difficult to develop resistance 
when given in the native dosage forms of Ayurvedic 
herbal drugs.  
 Central Council for Research in Ayurvedic 
Sciences is taken up clinical research in Malaria almost 
four decades ago with aim to develop a safe and 
effective new drug for Plasmodium Vivax malaria. It 
had also worked in association with National Malaria 
Eradication programme and Government of Haryana 
and carried out collaborative field trials at primary 
health centres of Gurgaon district. Observations of this 
trial have confirmed the effectiveness of the coded 
Ayurvedic drug AYUSH-64 in clearing the malaria 
parasite with 67-86% range of efficacy(5).  
 Dr. Achanta Laxmipathi Research Centre for 
Ayurveda, a peripheral unit of Central Council for 
Research in Ayurvedic Sciences (Ministry of AYUSH, 
Government of India), is carried out clinical research 
on effect of different herbal and herbo-mineral 
compounds of Ayurveda on Plasmodium Vivax 
malaria. The present article is aiming to review these 
studies to conclude the best drug for Plasmodium 
Vivax malaria.  
MATERIALS AND METHODS 
 Malarial Patients positive for Plasmodium 
Vivax were selected from the Chennai Corporation 
Malaria clinic, located at Elephant gate area, Chennai 
city, Tamil Nadu, according to the selection criteria.  
For Curative trials of Malaria 
Criteria of inclusion 
1. Positive cases of Malaria (Plasmodium vivax) 
2. Periodic fever with chill and rigor 
Criteria of exclusion 
1. Age below 10 years and above 60 years 
2. Pregnant woman 
3. Malignant malaria 
4. Malaria caused by other species 
Criteria for withdrawal from the study 
1. Patient who is not coming for regular follow up 
2. Irregular drug intake  
For Malaria prophylactic trials 
Criteria of selection 
1. Age above 15 years and below 60 years 
2. History of frequent episodes of malarial fever 
with three or more attacks within one year 
period 
Criteria of exclusion 
1. Age below 15 years and above 60 years 
2. Pregnant woman 
3. Malignant malaria 
4. Suffering with any other serious systemic illness 
Criteria for withdrawal from the study 
1. Patient who is not coming for regular follow up 
2. Irregular trial drug intake  
Study design and Trial Drugs 
Study-I 
Design: Randomized Double blind control trial 
Trial drug: Ayush-64, 3gm/day in 3 divided doses for 
4 days. 
Control drug: Chloroquine 600mg + 30mg 
Primaquine – 1st Day,  
Chloroquine 600mg+15mg Primaquine – next 3 days 
Study-II 
Design: Single blind comparative study 
Trial drugs: Group-I: Saptaparnatvak ghanavati 
1500mg TID for 10 days. 
Group-II: coded drug AYUSH-64 3gm+ Spatika 
bhasma 500mg + Guducisatva 500mg: TID for 10 days. 
Group-III: Parijathapatra ghanavati 1.5gm TID for 7 
days. 
Study-III 
Design: Open trial 
Trial drug: Parijathapatra ghanavati 1.5gm thrice 
daily with lukewarm water for 7 days. 
Study -IV 
Design: Open trial 
Prophylactic study  
Trial drug: Indukanthaghritha (a medicated ghee) 10 
ml per day with lukewarm water for 28 days 
Source of drug supply: For above studies 1 to 3, 
drugs are supplied by Central Research Institute 
(Ayurveda), Patiala (CCRAS, M/o AYUSH, Govt. of 
India). 
Study –IV: IMPCOPS, Chennai.  
Criteria for assessment of results 
Study-I 
Responded: Total disappearance of malarial parasites 
with clinical improvement after treatment i.e. on sixth 
day is considered as responded. 
Not Responded: Non disappearance of parasite with 
or without clinical improvement. 
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Study-II and III 
Responded: Blood smear negative for Malaria parasite 
Plasmodium vivax after treatment period till 29th day 
Not Responded: Blood smear positive for Malaria 
parasite Plasmodium vivax after treatment period 
Study-IV 
Good response: Peripheral blood smear negative for 
plasmodium parasite till 360th day. 
Fair response: 1). Peripheral blood smear negative 
for plasmodium parasite till 300th day in cases with 
history of previous 3 attacks of malaria fever. 
2). Peripheral blood smear negative for plasmodium 
parasite till 270th day in cases with history of more 
than 3 previous attacks of malaria fever. 
Poor Response: Peripheral blood smear negative for 
plasmodium parasite till 240th day. 
No response: Appearance of plasmodium parasite in 
the blood before 90 days. 
Follow-up 
Curative trials 
Study-I: Follow-up was carried out for three months 
Study-III and III - drug intake for 7 days, there after 
weekly follow up for up to 29th day. 
Prophylactic trial:  
Study-IV: drug intake for 29 days, there after weekly 
follow up for up to 360th day.  
i.e. on 8th, 15th, 22nd, 29th, 36th, 43rd, 50th, 57th, 64th, 
90th, 120th, 150th, 180th, 210th, 240th, 270th, 300th, 330th 
and 360th days.  
Statistical analysis: Applied student’s ‘t’ test for 
assessment. 
Ethical issues: Voluntary informed consent was 
obtained from all the subjects who participated in the 
study, before starting clinical trial. 
DISCUSSION 
 In spite of advanced chemotherapy and 
development of new plant based drugs like 
artemisinins and vigorous attempts of vector control, 
between 2000 and 2015, the substantial expansion of 
malaria interventions led to only 58% decline in 
malaria mortality rates globally. This shows the 
necessity of invention as well as adoption of anti-
malarial drugs from indigenous systems of medicine 
world-wide. Keeping this and national priority of 
malaria control in view the Central Council for 
Research in Ayurvedic Sciences, the apex body for 
research in Ayurvedic system of medicine has taken 
up the job of development of safe and effective anti-
malarial drugs. As a part of that programme, Dr. A. 
Lakshmipathi Research Centre for Ayurveda, Chennai, 
one of the peripheral institutes of Central Council for 
Research in Ayurvedic Sciences, Ministry of AYUSH, 
Government of India, has carried out series of clinical 
trials with herbal as well as herbo-mineral drugs on 
Plasmodium Vivax malaria for around three decades. 
The present article is written to review/judge the best 
anti-malarial herbal or herbo-mineral drug after 
analyzing the studies carried out at the Achanta 
Laxmipathi Research Centre for Ayurveda, Chennai 
and corresponding author is one of the investigators 
of Study-III and IV.  
Study-I was carried out on Randomized 
Double blind basis with trial and control groups; trial 
drug Ayush-64 was given to 29 subjects and standard 
modern anti-malarial drugs Chloroquine + Primaquine 
to 30 subjects as control drug. Besides clinical 
response (absence of fever), absence of malaria 
parasite after treatment period was taken as the 
criteria for assessing the efficacy of the drug. Out of 29 
cases who received Ayush-64, 21 cases responded 
well to the treatment and the other eight were 
declared as failure. So far the disappearance of Malaria 
parasite was concerned nearly 95% cases in the 
control group and 90.5% in Ayush-64 group become 
free from parasites on fourth day respectively. In this 
study it was concluded the trial drug Ayush-64 was 
found to possess good anti-malarial property with 
positive result in 72.41% as compared to 100% in 
control group (Table-I). The follow-up study carried 
out for three months indicate that there was no 
relapse in any of the case in both the treated groups (6). 
Before initiating the study toxicity studies of the drug 
was conducted by the Achanta Laxmipathi Research 
Centre for Ayurveda, Chennai, and found that the drug 
did not possess any toxicity at the dose of 500mg/kg 
when fed orally to rats for a period of four weeks. 
There was no side effect or toxic manifestation worth 
considering during the course of the study and follow-
up in any of the treated groups.  
 Study II was carried out under three trial 
groups – Group-I with Saptaparnatvak ghanavati (49 
subjects), Group-II with tab. Ayush-64, along with 
Spatika bhasma and Guducisatva (100 subjects) and 
Group III with Parijatapatra ghanavati (114 subjects). 
Positive response was observed in 23 (47%) numbers 
in Group-I, 50 (50%) in Group-II and 78 (68.4%) in 
Group-III (Table II).  
Among the above three groups in study-II, 
group-III i.e. single herbal drug Parijatapatra 
ghanavati was found more efficacious. Based on the 
encouraging results of Group-III, next trial i.e. study-III 
was taken up with the single drug Parijatapatra 
ghanavati and successfully completed on total 31 
subjects. This study was a open label study and shown 
highly positive response in 28 cases of Plasmodium 
Vivax Malaria with 90.32% of cure rate. These 28 
cases did not show any relapse till day 29th. Remaining 
03 cases had shown relapse, in 01 case smear was 
positive on day 15, in 02 cases smear was positive on 
day 22 (7) (Table –III).  
Study-IV was a prophylactic trial taken up to 
evaluate the efficacy of a medicated ghee 
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Indukanthaghrita, which is popularly used in Kerala 
state. Study carried out on total 67 patients, of which, 
35 (74.46%) showed Good response, 11 (23.40%) 
showed Fair response but, 01 (02.12%) cases did not 
show any response; 09 patients were dropped out 
from the study due to irregular drug intake(8) (Table 
IV).  
Details of Drugs used in these formulations 
Study-I  
 Herbal compound drug Ayush-64 contains 
Alstonia scholaris (L.) R. Br., Swertia chirata Bunch 
Ham. [Swertia chirayayita (Roxb .ex flem) Karst.], 
Caesalpinia Crista Linn. [C. bonduc (L) Roxb.] and 
Picrorhiza kurroa Royle ex Benth.  
Central Council for Research in Ayurvedic 
Sciences, Ministry of AYUSH, Govt. of India carried out 
a series of experimental and pharmacological studies 
on Ayush-64. This drug at doses of 100, 250, 500 and 
750 mg/kg body weight administered orally showed 
an appreciable anti-malarial property when tested on 
Plasmodium berghei infected albino mice.  
 Experimental studies carried out with Ayush-
64 for its anti-malarial effect on albino rats and the 
study shows that it is not effective against 
Plasmodium berghei in experimental animals(9).  
The above council also carried out 
experimental studies to assess the anti-malarial 
activity of active principles Echitamine chloride from 
Alstonia scholaris, Swerchirin from Swertia chirata and 
β-Caesalpin from Caesalpinea bonducella in rats. 
Echitamine chloride had shown anti-malarial activity 
at the dose of 320micro gram/K.g. (sub-cutaneous 
route) and 1.6 mg/kg (Oral route). Swerchirin had 
shown anti-malarial effect at the doses of 320 micro 
gram/K.g. and 1.6 mg/kg in both the oral as well as 
sub-cutaneous routes. Whereas β-Caesalpin was found 
to have anti-malarial effect at the dose of 1.6 mg/kg in 
both oral as well as sub-cutaneous routes (10).  
LD 50 value of Ayush-64 in mice by oral route 
is more than 2gm/kg while in rats it was more than 
4gm/kg. In subacute studies the drug in the dose of 
500mg/kg orally for a period of 12 weeks was 
considered absolutely safe. In acute toxicity studies, it 
was found to be non-toxic up to the dose of 10g/kg, 
when given orally to mice (11). 
Study II  
Group-I: single herbal drug Alstonia scholaris (L.) R. 
Br.  
Group-II: Herbal drugs: Ayush-64 (Alstonia scholaris 
(L.) R. Br., Swertia chirata Bunch Ham. (Swertia 
chirayayita (Roxb .ex flem) Karst., Caesalpinia Crista 
Linn. [C. bonduc (L) Roxb.] and Picrorhiza kurroa 
Royle ex Benth) + water extract of Tinospora cordifolia 
(Willd.) Miers. + Mineral drug: Spatika bhasma (Alum)  
Group-III: single herbal drug Nyctanthes arbortristis 
Linn. 
Study-III: single herbal drug Nyctanthes arbortristis 
Linn. 
Main anti-malarial drugs evaluated in these trails are - 
Tab. Ayush-64, Kiratatikta (Swertia chirayita (Roxb. 
Ex Flem.), Latakaranja (Caesalpinia bonducella), 
Saptaparna (Alstonia scholaris R.Br.) and Parijata 
(Nyctanthes arbor-tristis Linn.), remaining drugs of the 
above formulations are supportive only. Hence the 
main drugs are discussed below for their comparative 
effect.  
Kiratatikta (Swertia chirayita (Roxb. Ex Flem.)  
 The chiretta is much prized in India as a tonic 
and bitter without aroma or astringency. It possesses 
the property of bitter tonic but unlike most other 
bitters it does not constipate the bowels. Instead it 
tends to produce a regular action and causes a free 
discharge of bile. In Indian medicine, chiretta is 
prescribed in a variety of forms and combinations in 
chronic fevers.  
 Chiretta is reported to contain a yellow bitter 
acid, ophelic acid (C15H20O13), two bitter glucosides, 
chiratin (C26H48O15) and amarogentin (C32H38O16), 
xanthone, swerchirin (C25H13O6). Amarogentin is one 
of the bitterest substances known. (12)  
Latakaranja (Caesalpinia bonducella) 
 The three new cassane furanoditerpenoids (1-
3) together with known cassane diterpenes were 
isolated from the seed kernels of Caesalpinia bonduc 
compound 1-3 exhibited good anti-malarial activity 
against multi drug resistant K1 strain of Plasmodium 
falciparum(13). Kalauni et al has reported antimalarial 
activity of cassane and norcassane type of diterpenes 
from Caesalpinia crista and their structure activity 
relationship (14). Linn et al has reported cassane and 
norcassane type diterpene from Caesalpinia crista of 
Indonasia and their antimalarial activity against the 
growth of plasmodium falciparum(15).  
Saptaparna (Alstonia scholaris R.Br.) 
 Commonly known as Devil’s tree. The bark is 
regarded as bitter tonic and a mild febrifuge, and 
possesses astringent, anthelmintic and galactogogue 
properties. The total alkaloidal content in the Indian 
bark is reported to be 0.16-0.27%, with echitamine as 
the chief constituent, and echitamidine in small 
quantities. The total alkaloids and the tincture made 
from the bark showed little or no demonstrable action 
on malaria; also no synergistic action with quinine 
was observed (16). Gandhi and Vinayak reported the 
antimalarial activity of this drug (17).  
Parijata (Nyctanthes arbor-tristis Linn.) 
 It is commonly known as Night Jasmine. 
Among all the drugs discussed in this paper, the drug 
Parijata is found most efficacious among all. Leaves of 
this plant contain tannic acid, methyl salicylate, an 
amorphous glycoside, mannitol, an amorphous resin 
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and a trace of volatile oil. They also contain ascorbic 
acid (30mg/100g.) and carotene (18).  
Parijata is found to have anti-malarial and 
antipyretic and antimicrobial properties on 
pharmacological screening (19). Fresh paste of leaves of 
this plant also tried clinically for its safety and anti-
malarial efficacy in around 120 patients, 92 (76.6%) 
patients had shown complete relief (20). Aminuddin et 
al (21) and Badam L Rao et al (21) are also reported the 
anti-malarial activity of Parijata.  
Prophylactic study 
Study-IV: Compound herbal ghee preparation 
contains Caesalpinia Crista Linn. [C. bonduc (L) Roxb.], 
Cedrus deodara (Roxb.) Loud are main ingredients. In 
this study a medicated ghee Indukantaghrita 
evaluated for its prophylactic activity against Malaria. 
Main ingredients of trail drug Indukanthaghrita are 
Devadaru, Putikaranja etc. Devadaru (Cedrus deodara) 
is having Krimighna (anthelmintic) property. The bark 
is said as useful in remittent and intermittent fevers. 
Putikaranja or Latakaranja the other main drug is 
already discussed above.  
CONCLUSION 
1. From 17th century onwards treating of Malaria is 
started with Cinchona bark. After successful 
invention of chemotherapy, the world was relaxed 
about Malaria. But after observing resistance to 
chemotherapy drugs, big question arouse about 
the eradication of Malaria. 
2. World started looking after alternate systems of 
medicine, and artemisinins created a ray of hope.  
3. Now it is very shocking to know about the 
resistance to artemisinins in South East Asia 
region.  
4. It is the peak time to go for new, alternative, 
effective and safe drugs from traditional systems 
of medicine.  
5. This paper too have worked on the aim of finding 
a new, safe, effective plant based drug, based on 
the drugs of Ayurvedic pharmacology and clinical 
studies done on Vivax Malaria. 
6. An elaborative analysis done on the studies 
carried exclusively by Dr. Achanta Laxmipathi 
Research Centre for Ayurveda, Chennai, is one of 
units of the Central Council for Research in 
Ayurvedic Sciences, worked extensively on Vivax 
Malaria. 
7. Drugs reviewed for Anti-malarial effect are Tab. 
Ayush-64, Kiratatikta (Swertia chirayita (Roxb. Ex 
Flem.), Latakaranja (Caesalpinia bonducella), 
Saptaparna (Alstonia scholaris R.Br.) and Parijata 
(Nyctanthes arbor-tristis Linn.). 
8. Among these drugs, Parijata (Nyctanthes arbor-
tristis Linn.) was found highly effective as well safe 
drug (Chart-I).  
9. This article concludes that the pharmaceutical 
form used in administering Cinchona officinalis 
and Artemisia ammua, should not be done with 
Parijata, the new world scientists must evaluate 
Parijata in the traditional form prescribed by the 
Ayurvedic system of medicine like paste of the 
leaf, or tablets made of water extract of the leaf. By 
this only drug resistance to Malaria can be 
avoided.  
Table -I: Results of Study-I 
 Responded  Not responded  
Trial group (n=29)  21 (72.41%)  08 (27.59%)  
Control group (n=30)  30 (100%)  00  







Table-III: Results of Study-III 
 Responded  Not responded  
Parijatapatra ghanavati (n=31)  28 (90.32%)  03 (09.68%)  
Table-IV: Results of Study-IV 
 Good response  Fair response  Poor response  No response  
Indukanthagrutha 
(n=47)  
35 (74.46%)  11 (23.40%)  00  01 (2.12%)  
 Responded  Poor response  
Group-I (n= 49)  23 (47%)  26 (53%)  
Group-II (n=100)  50 (50%)  50 (50%)  
Group-III (n=114)  78 (68.4%)  36 (31.6%)  
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Chart-I: Comparison of Results of Malaria curative trails 
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